TPA Opposes Lowering Drug Costs for American Families Act

Today, the Taxpayers Protection Alliance (TPA) sent a letter to the Chairs of the House Energy and Commerce, Ways and Means, and Education and the Workforce Committees opposing consideration of the Lowering Drug Costs for American Families Act.  This counterintuitive, unserious proposal from the Ranking Members of these committees will expands the Inflation Reduction Act’s (IRA) flawed drug pricing provisions, resulting in more price controls and less access to life-saving treatments. Despite its claims, the IRA did not create a negotiation structure between the pharmaceutical industry and taxpayer-funded healthcare plans. Instead, it created a non-negotiable ultimatum for drug manufacturers: agree to the government-set price, pay a tax between 185.71 and 1,900 percent on gross sales for a medicine, or remove all the covered companies’ treatments from Medicare and Medicaid. These policies severely hamper the industry’s ability to innovate and produce cures for the most pervasive illnesses in our country and around the world. 

Read TPA’s full letter here and below.